BioMérieux Publishes Q3 2026 Results Call Transcript
- BioMérieux held its Q3 2026 results call November 3 with CEO Pierre Boulud, CFO Guillaume Bouhours and investor-relations head Aymeric Fichet.
- Management reaffirmed full-year organic sales growth guidance of 3%-5%, with CEBIT growth expected at 0%-10%.
- Quarterly organic sales rose 8%; unchanged fourth-quarter respiratory activity versus 2025 would put annual growth at the guidance range’s lower end.
- BIOFIRE non-respiratory sales grew 25%, or 15% excluding the Cyclospora outbreak benefit; management cautioned against extrapolating the underlying performance.
- The estimated full-year foreign-exchange headwind narrowed to EUR 35 million from EUR 40 million-EUR 50 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMérieux SA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.